MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT
Maximize your positive impact through the Crystal Ball Event Series by MarketsandMarkets
HEALTHCARE

MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)

High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event

The end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and biobetters, plasma therapy as well as others.

A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc can benefit from this unprecedented growth over the next 5 years.

This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space

What to Expect

Key
Highlights

  • Continuous biomanufacturing is expected to double in the next 5 years, garnering larger share from conventional batch processing.
  • Alternative and Novel downstream bioprocessing techniques generate a significant share of over $16 billion growth overall.
  • Increasing demand for major end products led by monoclonal antibodies, vaccines, biosimilars, biobetters, plasma therapy, cell & gene therapy and human microbiome therapeutics, are growing at 3 times the rate of conventional therapeutics.

Crystal Ball:
Through the Speakers Perspective

  • How can Cell therapy market expand faster in non-oncology indications & out of US and how can this transition be expedited?
  • Which technologies can result in the improvement of production yields and optimize supply chain of COVID-19 vaccine?
  • Why is the mRNA vaccine approval so pivotal for the future of disease therapeutics?
  • What could be characteristics for an ideal biotech innovator &CROs/CMOs cooperation for accelerating development and commercialization of cell-based therapeutics?
Bioproduction Website Infographic

Conference Speakers

We are targeting speakers and Participants from potential companies like Merck KGA, Lonza, Bio-Rad Laboratories,Charles River Laboratories, MaxCyte, Becton, Dickinson & Co, FUJIFILM Irvine Scientific, bioMérieux,Foxx Life Sciences, InvivoGen, Patheon Inc, Cytovance Biologics,  Greiner Bio-One, Cellexus, ABECK Group, G&G Technologies Inc etc.

Confirmed Speakers

Rajesh Desikan

Rajesh Desikan

Vice President & Head, US Marketing, Oncology & Immunology Biosimilars, Fresenius Kabi, USA

Dominic Clarke

Dominic Clarke

Global Head Cell Therapy, Strategy and Innovation, , Charles River Laboratories

Kenneth Lee

Kenneth Lee

Head of Commercial Division, Americas, GenScript ProBio

Peter Levison

Peter Levison

Executive Director - Business Development, Pall Corporation

Ratish Krishnan

Ratish Krishnan

Associate Director for Cell & Gene Therapy BioProcessing, MilliporeSigma

View All Speakers

Conference Partners

Media Partners

PharmaVOICE

PharmaVOICE

PharmaTutor

PharmaTutor

Pharma Journalist

Pharma Journalist

Connect with us
Top Market Reports | Conferences | Research Insight | Blog | New Reports
© 2021 MarketsandMarkets Research Private Ltd. All rights reserved
Subscribe Newsletter
By subscribing to our mailing list you will always get latest news from us.